ERBB2 and cancer: In contrast, Ogawa et al.10 conducted a retrospective study for intensive follow-up; no difference was observed between symptomatic/asymptomatic MBC and ER receptor and HER2 status, although the authors included both MBC and cancer with locoregional recurrence only.